— Achieve Life Sciences (NASDAQ: ACHV)
reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a
loss of $3.6 million, or $0.55 per share, last year.
— Total operating expenses were $3.2 million.
— At December 31, 2019, cash, cash equivalents and
restricted cash was $16.7 million.
— Achieve Life Sciences completed
a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical
development program.
— The company established an
agreement with the FreeMind Group to assist in securing non-dilutive funding to
evaluate cytisinicline in vapers and e-cigarette users.
— The company closed an underwritten
public offering for gross proceeds of $13.8 million, before
underwriting discounts and commissions and offering expenses.
— ACHV shares were up 12.7% in premarket hours on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.